MedPath

Irinotecan

Generic Name
Irinotecan
Brand Names
Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
Drug Type
Small Molecule
Chemical Formula
C33H38N4O6
CAS Number
97682-44-5
Unique Ingredient Identifier
7673326042
Background

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Indication

For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
Associated Therapies
-

Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer

Phase 2
Conditions
Small Cell Carcinoma of Lung
Interventions
First Posted Date
2012-07-09
Last Posted Date
2012-07-09
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
50
Registration Number
NCT01635400
Locations
🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI

Phase 2
Completed
Conditions
Solid Tumors
Interventions
First Posted Date
2012-07-06
Last Posted Date
2019-02-26
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
29
Registration Number
NCT01634555
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Pittsburgh, Pennsylvania, United States

Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC

Not Applicable
Withdrawn
Conditions
Liver Metastases
Colorectal Cancer
Interventions
Device: DC Bead™
Drug: Cetuximab
Drug: 5 FU
Drug: Irinotecan
First Posted Date
2012-06-29
Last Posted Date
2014-12-04
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
Registration Number
NCT01631539

A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)

Phase 2
Terminated
Conditions
Rectal Neoplasms
Interventions
First Posted Date
2012-05-31
Last Posted Date
2020-05-04
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
11
Registration Number
NCT01609231

Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer

Phase 1
Terminated
Conditions
Non-small Cell Lung Cancer
Interventions
First Posted Date
2012-05-30
Last Posted Date
2018-05-22
Lead Sponsor
New Mexico Cancer Care Alliance
Target Recruit Count
2
Registration Number
NCT01607554
Locations
🇺🇸

New Mexico Cancer Care Associates, Santa Fe, New Mexico, United States

🇺🇸

Hematology Oncology Associates, Albuquerque, New Mexico, United States

🇺🇸

University of New Mexico Cancer Center, Albuquerque, New Mexico, United States

Study of MLN8237 in Combination With Irinotecan and Temozolomide

Phase 1
Completed
Conditions
Neuroblastoma
Interventions
First Posted Date
2012-05-18
Last Posted Date
2019-07-31
Lead Sponsor
New Approaches to Neuroblastoma Therapy Consortium
Target Recruit Count
54
Registration Number
NCT01601535
Locations
🇺🇸

Children's Healthcare of Atlanta, Atlanta, Georgia, United States

🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

Childrens Hospital Boston, Dana-Farber Cancer Institute., Boston, Massachusetts, United States

and more 10 locations

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

First Posted Date
2012-05-08
Last Posted Date
2017-09-19
Lead Sponsor
Sanofi
Target Recruit Count
37
Registration Number
NCT01593228
Locations
🇺🇸

Investigational Site Number 840025, Sioux City, Iowa, United States

🇺🇸

Investigational Site Number 840030, Boston, Massachusetts, United States

🇺🇸

Investigational Site Number 840043, Cleveland, Ohio, United States

and more 29 locations

A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer

Phase 4
Completed
Conditions
Colorectal Neoplasms
Interventions
First Posted Date
2012-05-01
Last Posted Date
2019-01-22
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
128
Registration Number
NCT01588990
Locations
🇦🇺

Calvary North Adelaide; North Adeliade Oncology Centre, North Adelaide, South Australia, Australia

🇦🇺

Canberra Hospital, Garran, Australian Capital Territory, Australia

🇦🇺

Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia

and more 14 locations

FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer

Phase 3
Conditions
Colorectal Cancer
Interventions
First Posted Date
2012-03-30
Last Posted Date
2012-03-30
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
200
Registration Number
NCT01566942
Locations
🇨🇳

the first affiliated hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas

Phase 2
Completed
Conditions
Pancreatic Cancer
Interventions
First Posted Date
2012-03-22
Last Posted Date
2020-08-10
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
34
Registration Number
NCT01560949
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath